Vaccine plant problems put Sanofi shot supplies in dire straits

Last year, the FDA came down hard on a Sanofi Pasteur plant in Toronto. The ensuing trouble triggered serious supply problems--and, in turn, a shortage of childhood vaccines in the U.S. Sanofi's ($SNY) third-quarter vaccines sales took a big hit from that shortage, and supply won't be back to normal till the first quarter of 2014. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.